Author: ZHANG, Xuanguo; XI, Li; PANG, Fang; DU, Yan; YUAN, Qiuzhen; SHI, Minjuan; LIU, Jiping; MA, Hui; LI, Bo
Title: Convalescent Plasma in the Treatment of Severe COVID-19: A Systematic Review and Meta-Analysis Cord-id: f5hrgykc Document date: 2020_11_25
ID: f5hrgykc
Snippet: BACKGROUND: COVID-19 is a public health emergency of international concern. Its incidence rates and mortality are very high; however, so far, an effective drug treatment remains unknown. Based on the role of convalescent plasma therapy in previously identified viral pneumonias, patients with severe COVID-19 have been given this therapy. This systematic review and meta-analysis aimed to summarize the clinical evidence regarding the efficacy and safety of convalescent plasma therapy in the treatme
Document: BACKGROUND: COVID-19 is a public health emergency of international concern. Its incidence rates and mortality are very high; however, so far, an effective drug treatment remains unknown. Based on the role of convalescent plasma therapy in previously identified viral pneumonias, patients with severe COVID-19 have been given this therapy. This systematic review and meta-analysis aimed to summarize the clinical evidence regarding the efficacy and safety of convalescent plasma therapy in the treatment of severe COVID-19. METHODS: PubMed, Embase, Ovid, China Knowledge Network, China Biomedical, VIP Chinese Sci-tech Journal, Wanfang Database, and the International Clinical Trials Registry Platform were searched up to 21 June 2020, to identify clinical studies and registered trials on the use of convalescent plasma in the treatment of critically ill patients with COVID-19. Stata 13.0 was used to perform Meta-analysis. All records were screened as per the protocol eligibility criteria. RESULTS: Nineteen clinical reports regarding convalescent plasma in the treatment of severe COVID-19 were included. Through systematic analysis, convalescent plasma was found to yield some efficacy on severe COVID-19 and had almost no obvious adverse reactions. CONCLUSION: Convalescent plasma therapy seems to yield some efficacy among patients with severe COVID-19 and almost no obvious adverse reactions were found. However, at present, the clinical evidence is insufficient, and there is an urgent need for support from high-quality clinical trial data.
Search related documents:
Co phrase search for related documents- abo compatible human and lung injury: 1, 2
- abo compatible human convalescent plasma and acute lung injury: 1, 2
- abo compatible human convalescent plasma and lung injury: 1, 2
- abo compatible human convalescent plasma transfusion and acute lung injury: 1, 2
- abo compatible human convalescent plasma transfusion and lung injury: 1, 2
- abstract title and acute respiratory infection: 1, 2, 3
- abstract title read and acute respiratory infection: 1
- accurate conclusion and acid detection: 1, 2
- accurate conclusion and acute respiratory infection: 1, 2
- accurate conclusion and lymphocyte count: 1
- acid detection and acute respiratory infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acid detection and lung injury: 1, 2
- acid detection and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acid detection and lymphocyte white blood cell: 1, 2
- acid detection and lymphocyte white blood cell count: 1, 2
- acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury and lymphocyte count: 1, 2, 3
- acute respiratory infection and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory infection and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date